在激素受体阳性乳腺癌中使用免疫检查点抑制剂治疗
David Lin1, Jin Sun Lee Bitar1, Isabella Ma1
1Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
International journal of molecular sciences
|December 30, 2025
概括
免疫检查点抑制剂 (ICI) 在早期HR+/HER2乳腺癌中表现有前途,但需要更多的研究来确定常规使用. 目前的策略旨在改善瘤免疫性,以获得更好的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 免疫检查点抑制剂 (ICI) 已在三阴性乳腺癌 (TNBC) 治疗中建立.
- 将其纳入激素受体阳性,人体表皮生长因子受体2-阴性 (HR+/HER2-) 乳腺癌中,因免疫性较差而受到限制.
- 新的战略重点是增强HR+/HER2-乳腺癌中的瘤免疫性.
研究的目的:
- 审查乳腺癌临床开发中的免疫疗法.
- 提供最新的临床试验结果,重点关注HR+/HER2-乳腺癌.
- 评估免疫治疗在HR+/HER2-乳腺癌中的潜力.
主要方法:
- 对当前免疫疗法临床试验的审查.
- 对临床结果和生存数据的分析.
- 专注于改善"免疫感冒"瘤中的免疫原性策略.
主要成果:
- 在TNBC,ICI已经改善了结果.
- 早期的试验表明,在高风险,早期的HR+/HER2-乳腺癌中,ICI的潜力很大.
- 目前没有足够的证据支持HR+乳腺癌的常规免疫疗法使用.
结论:
- 需要进行长期随访,以确定HR+乳腺癌免疫治疗对生存的影响.
- 需要进一步的研究来确定免疫治疗在HR+/HER2-乳腺癌中的疗效.
- 组合策略对于克服免疫性障碍至关重要.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.4K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
3.7K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
